Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 117Terminated 23Recruiting 20Not yet recruiting 9Withdrawn 6Unknown 6Active not recruiting 5Suspended 1No longer available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Breast Neoplasms 32Neoplasms 28Colorectal Neoplasms 19Prostatic Neoplasms 16Lung Neoplasms 13Leukemia, Myeloid, Acute 12Glioblastoma 12Stomach Neoplasms 10Head and Neck Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Melanoma 8Glioma 8Brain Neoplasms 8Rectal Neoplasms 7Carcinoma, Hepatocellular 7Ovarian Neoplasms 6Neoplasm Metastasis 6Hematologic Neoplasms 6Uterine Cervical Neoplasms 5Polycystic Ovary Syndrome 5Myelodysplastic Syndromes 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Lymphoma, B-Cell 4Lymphoma 4Depression 4

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × OTHER × Dendritic Cell Sarcoma, Interdigitating × Clear all
NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡